Geron Corporation

What they do

Geron received FDA approval of RYTELO on June 6, 2024 for adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs), and commercially launched the product in the U.S. in June 2024. In March 2025 the European Commission approved RYTELO for adults with transfusion-dependent anemia due to lower-risk MDS without an isolated deletion 5q abnormality who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The company also develops imetelstat in other myeloid malignancies, including the Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint. It works with third parties such as Tanner Pharma for named patient programs outside the U.S. and is preparing for a planned EU launch.

Revenue drivers

• RYTELO (imetelstat) U.S. net product revenue — U.S. sales of RYTELO in lower-risk MDS are the company's only approved product revenue; Q2 2026 net product revenue was $57.5 million, up from $49.0 million in Q2 2025, and the company reiterated 2026 guidance of $220 million to $240 million.
• RYTELO EU commercialization — The EC approved RYTELO in March 2025 for certain lower-risk MDS patients, and Geron is preparing for planned commercialization in select EU markets in 2026 while working with third parties on reimbursement, health technology assessment, market access and distribution; no EU product revenue has been reported.
• Named patient programs (NPPs) outside the U.S. — Geron partnered with Tanner Pharma in 2025 to enable paid access outside the U.S. through approved NPPs; the company states product revenue from NPPs to date has been minimal.
• Potential IMpactMF label expansion — The Phase 3 IMpactMF trial in relapsed/refractory MF, if positive and approved for label expansion, could significantly increase the RYTELO commercial opportunity, but it does not currently generate revenue.

Recent performance

For Q2 2026, Geron reported RYTELO net product revenue of $57.5 million, an increase of 11% compared to Q1 2026 ($51.8 million) and up from $49.0 million in Q2 2025. RYTELO demand grew 5% quarter over quarter, and ordering accounts increased roughly 8% to approximately 1,575. Total costs and operating expenses were $70.0 million, versus $61.5 million in Q2 2025, with the increase primarily due to non-cash inventory-related expenses; cost of goods sold was $9.2 million versus $1.2 million. The company reported a net loss of $16.7 million, or $0.02 per share, compared to $16.4 million, or $0.02 per share, a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $326.9 million as of June 30, 2026.

Strategy

Management's stated strategy is to maximize the value of RYTELO by driving new patient starts across eligible lower-risk MDS segments, particularly second-line, reinforcing the value of observed treatment duration with health care providers, educating on safety management, and leveraging payor access. The company is pursuing paths to bring RYTELO to eligible patients outside the U.S., including preparing for planned commercialization in select EU markets in 2026 with third parties handling reimbursement, HTA, market access and distribution. It also plans to advance the Phase 3 IMpactMF trial in relapsed/refractory MF and to assess imetelstat in additional hematologic malignancies or as a combination therapy. The company cited an estimated 8,000 second-line lower-risk MDS patients in the U.S. as a growth opportunity.

Risks

• Dependence on RYTELO — The company states its near-term prospects are wholly dependent on RYTELO, its only FDA-approved product, and that its ability to generate meaningful revenue or achieve profitability depends on successfully commercializing RYTELO in the U.S. for lower-risk MDS or expanding its indications.
• Limited commercialization experience — Geron notes the RYTELO launch marks its first commercial launch of a product candidate, and its ability to grow revenue on a sustained basis has not yet been proven.
• IMpactMF trial uncertainty — The Phase 3 IMpactMF trial in relapsed/refractory MF may not have a positive outcome, and projected death event rates may differ from actual rates, potentially delaying the planned interim analysis in the second half of 2026 and final analysis in the second half of 2028.
• Manufacturing and supply — The company lists as a risk whether failures or delays in manufacturing or supplying sufficient quantities of RYTELO or clinical trial materials could impact commercialization or continuation of IMpactMF and other trials.

Outlook

Geron reiterated 2026 guidance for RYTELO net product revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million. Management expects the interim overall survival analysis in IMpactMF may occur in the second half of 2026, with the final analysis potentially in the second half of 2028, based on current event-rate assumptions. The company is preparing for planned commercialization of RYTELO in select EU markets in 2026. It ended Q2 2026 with $326.9 million in cash, cash equivalents, restricted cash and marketable securities, which it states provides cash for the foreseeable future.